Insider trading today includes a notable open-market purchase at Scribe Therapeutics, Inc. (SCTX). A Form 4 filing shows OrbiMed Advisors LLC, listed as a director of the gene-editing company, bought 1,000,000 shares on July 27, 2026, at $15.00 per share for a total outlay of $15,000,000.
The transaction was an open-market buy, meaning OrbiMed used its own capital to acquire the stock rather than receiving shares through options, grants, or other compensation-related mechanisms. Following the purchase, OrbiMed’s holdings stand at 1,348,825 shares, held indirectly through an entity structure such as a fund or investment vehicle rather than in the director’s own name.
A Sizable Bet at $15 a Share
A $15 million purchase is a meaningful commitment for any single filing, and the price point of $15.00 per share gives investors a clear marker of where OrbiMed was willing to deploy capital. Because the shares are held indirectly, the position reflects OrbiMed’s broader investment vehicle rather than a personal holding, which is common for institutional directors who sit on company boards through their fund’s board seat.
This purchase adds to a broader pattern of insider activity at Scribe Therapeutics. As detailed in our earlier coverage, SCTX Insider Cluster Buy: Director Adds to $36M Buying Spree, multiple insiders have been adding to their positions in recent weeks, a pattern sometimes referred to as cluster buying.
Why Clustered Buying Draws Attention
Academic research on insider trading has found that clusters of purchases by multiple insiders at the same company have historically shown a statistical correlation with subsequent stock outperformance, though the relationship is not guaranteed and varies across companies and time periods. This filing does not indicate whether Scribe Therapeutics shares will rise or fall, and the disclosure itself is simply a record of a transaction that already occurred.
Our classification tags this filing as an open market buy, the most straightforward and often most closely watched category of insider transaction, since it represents a discretionary decision to purchase shares at prevailing market prices rather than an automatic or compensation-driven event. Readers tracking top insider trades today may want to watch for additional filings tied to Scribe Therapeutics in the coming weeks, particularly given the pattern of insider activity already on record at the company.
Source: original SEC Form 4 filing.